Solid Tumors Market report gives strength to organization and makes better decisions for steering the business on the right track. A strong research methodology used comprises of data models that include market overview and guide, vendor positioning grid, market time line analysis, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis and vendor share analysis. Moreover, only dependable sources such as journals, newspapers, company websites, and annual reports of the companies have been referred to collect the data which can be trusted confidently. It suits the requirements of small, medium as well as large size of businesses.

Data Bridge Market Research analyses that the Solid Tumors Market was valued at USD 209.61 billion in 2021 and is expected to reach USD 901.27 billion by 2029, registering a CAGR of 20.0% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Recent Development

In May 2021, Amgen announced the U.S. Food and Drug Administration (FDA) approval for LUMAKRAS (sotorasib) for treating adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. LUMAKRAS was given priority approval due to its high overall response rate (ORR) and short response time. Continued approval for this indication could be conditional on a confirmatory trial demonstrating and documenting clinical trials.

View Detailed Solid Tumors Market Report@ https://www.databridgemarketresearch.com/reports/global-solid-tumors-market

Some of the major players operating in the solid tumors market are:

• Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Merck Co., Inc. (U.S.)
• Allergan (Ireland)
• AstraZeneca (U.K.)
• Johnson Johnson Private Limited (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Bayer AG (Germany)
• Boehringer Ingelheim International GmbH. (Germany)
• Reddy’s Laboratories Ltd. (India)
• Gilead Sciences, Inc. (U.S.)
• Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• AbbVie Inc. (U.S.)
• Lupin (India)

Explore DBMR Comprehensive Coverage on Healthcare Domain:

Metastatic Solid Tumors Market – Industry Trends and Forecast to 2029 https://www.databridgemarketresearch.com/reports/global-metastatic-solid-tumors-market

Neuroendocrine Tumors Market – Industry Trends and Forecast to 2028 https://www.databridgemarketresearch.com/reports/global-neuroendocrine-tumors-market